Nisreen Ezzi, MD
Family Medicine · Hicksville, NYNPI 1912231010
Payments from drug & device makers
Across 549 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$2K
- GSK$1K
- Lilly USA, LLC$675
- Novo Nordisk$596
- Boehringer Ingelheim$563
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $1,732 |
| Amgen(2 entities) | 102 | $1,521 |
| GSK | 68 | $1,021 |
| Lilly USA, LLC | 45 | $675 |
| Novo Nordisk | 32 | $596 |
| Boehringer Ingelheim | 29 | $563 |
| AbbVie | 36 | $558 |
| Scilex Pharmaceuticals Inc. | 29 | $554 |
| Merck | 14 | $259 |
| Pfizer | 19 | $245 |
| Shield Therapeutics Inc | 14 | $242 |
| Amarin Pharma, Inc. | 15 | $240 |
| Novartis | 9 | $154 |
| Dexcom, Inc. | 9 | $144 |
| Exact Sciences | 6 | $102 |
| Mannkind Corporation | 5 | $88 |
| Renalytix AI, Inc. | 4 | $84 |
| Astellas Pharma US Inc | 4 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Abbott | 3 | $70 |
| Amphastar Pharmaceuticals, Inc. | 3 | $65 |
| Dermavant Sciences, Inc. | 4 | $65 |
| Bayer | 3 | $62 |
| Evoke Pharma, Inc. | 3 | $55 |
| Genentech USA, Inc. | 3 | $43 |
| Cipher Pharmaceuticals US LLC | 1 | $42 |
| Lundbeck LLC | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,403 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 242 | $214,199 |
| JardianceEmpagliflozin | 162 | $181,369 |
| FarxigaDapagliflozin Propanediol | 137 | $112,959 |
| JanuviaSitagliptin Phosphate | 96 | $109,131 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $106,673 |
| ZtlidoLidocaine | 109 | $97,075 |
| OzempicSemaglutide | 62 | $93,931 |
| MounjaroTirzepatide | 56 | $73,360 |
| EliquisApixaban | 49 | $71,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $71,239 |
| VascepaIcosapent Ethyl | 110 | $70,198 |
| CrotanCrotamiton | 42 | $66,682 |
| Repatha SureclickEvolocumab | 34 | $47,438 |
| TrulicityDulaglutide | 28 | $36,423 |
| Diclofenac Potassium | 28 | $33,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $1,732 | $245,772303 claims |
| Boehringer IngelheimJardiance, Tradjenta | $563 | $194,246175 claims |
| MerckJanuvia, Janumet | $259 | $139,779130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $675 | $109,78484 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $554 | $97,075109 claims |
| Novo NordiskOzempic | $596 | $93,93162 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,021 | $84,507116 claims |
| PfizerEliquis | $245 | $71,84249 claims |
| AbbVieUbrelvy, Linzess | $558 | $62,35248 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $31,14845 claims |
| Mannkind CorporationAfrezza | $88 | $24,98925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Hicksville
- Mark SethnaHicksville$70K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.